» Articles » PMID: 28417976

Revealing Inhibition Difference Between PFI-2 Enantiomers Against SETD7 by Molecular Dynamics Simulations, Binding Free Energy Calculations and Unbinding Pathway Analysis

Overview
Journal Sci Rep
Specialty Science
Date 2017 Apr 19
PMID 28417976
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

SETD7 is associated with multiple diseases related signaling pathways. (R)-PFI-2 is the first SETD7 inhibitor with nanomolar inhibitory potency. The activity of (R)-PFI-2 is about 500 times over that of (S)-PFI-2. Understanding the mechanism behind this difference will be helpful to discovery and design of more potent SETD7 inhibitors. A computational study combining molecular dynamics simulation, binding free energy calculations, and residue interaction network (RIN) was performed on the (S)-PFI-2/SETD7 and (R)-PFI-2/SETD7 complexes to explore the molecular mechanism behind the different inhibition activity. The results from Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) calculation show (R)-PFI-2 has lower binding free energy. Residues H252, D256, L267, Y335, G336 and H339 are responsible for the binding of SETD7 to the (R)-PFI-2. RIN analysis indicates van der Waals interaction is critical for the binding of (R)-PFI-2. The results from adaptive basing force (ABF) simulation confirm that the free energy barrier of (R)-PFI-2 dissociating from the SETD7 is larger than that of (S)-PFI-2. (S)-PFI-2 and (R)-PFI-2 dissociate from the SETD7 binding site along different reaction coordinate and have potential mean of force (PMF) depth. Our simulations results will be useful to understand molecular mechanism of activity difference between PFI-2 enantiomers against SETD7.

Citing Articles

Effect of Fragment 1 on the Binding of Epigallocatechin Gallate to the PD-L1 Dimer Explored by Molecular Dynamics.

Guo Y, Guo Y, Guo Z, Liu B, Xu J Molecules. 2023; 28(23).

PMID: 38067610 PMC: 10708077. DOI: 10.3390/molecules28237881.


The role of SET domain containing lysine methyltransferase 7 in tumorigenesis and development.

Yang S, Wang X, Bai J, Duan B Cell Cycle. 2022; 22(3):269-275.

PMID: 36101480 PMC: 9851238. DOI: 10.1080/15384101.2022.2122257.


Insights into the stereoselectivity of human SETD7 methyltransferase.

Tang B, Li B, Li B, Qin J, Zhao J, Xu J RSC Adv. 2022; 9(16):9218-9227.

PMID: 35517649 PMC: 9062083. DOI: 10.1039/c9ra00190e.


Importance of protein flexibility in ranking ERK2 Type I inhibitor affinities: a computational study.

Niu Y, Yao X, Ji H RSC Adv. 2022; 9(22):12441-12454.

PMID: 35515820 PMC: 9063686. DOI: 10.1039/c9ra01657k.


Exploring the Molecular Basis of Substrate and Product Selectivities of Nocardicin Bifunctional Thioesterase.

Yu Q, Xie L, Li Y, Bai L, Zhao Y, Wei D Interdiscip Sci. 2021; 14(1):233-244.

PMID: 34699036 DOI: 10.1007/s12539-021-00482-z.


References
1.
Lindorff-Larsen K, Piana S, Palmo K, Maragakis P, Klepeis J, Dror R . Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins. 2010; 78(8):1950-8. PMC: 2970904. DOI: 10.1002/prot.22711. View

2.
Faller C, Reilly K, Hills Jr R, Guvench O . Peptide backbone sampling convergence with the adaptive biasing force algorithm. J Phys Chem B. 2012; 117(2):518-26. PMC: 3951443. DOI: 10.1021/jp309741j. View

3.
Niu Y, Pan D, Shi D, Bai Q, Liu H, Yao X . Influence of Chirality of Crizotinib on Its MTH1 Protein Inhibitory Activity: Insight from Molecular Dynamics Simulations and Binding Free Energy Calculations. PLoS One. 2015; 10(12):e0145219. PMC: 4683072. DOI: 10.1371/journal.pone.0145219. View

4.
Piovesan D, Minervini G, Tosatto S . The RING 2.0 web server for high quality residue interaction networks. Nucleic Acids Res. 2016; 44(W1):W367-74. PMC: 4987896. DOI: 10.1093/nar/gkw315. View

5.
Sun H, Li Y, Tian S, Xu L, Hou T . Assessing the performance of MM/PBSA and MM/GBSA methods. 4. Accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set. Phys Chem Chem Phys. 2014; 16(31):16719-29. DOI: 10.1039/c4cp01388c. View